Cenicriviroc, a molecule in Phase II clinical trials, which mechanism of action in NASH is targeting the suppression of CCR2/CCR5 genes, reduced NAS and fibrosis comparable to gemcabene in the STAMTM model [30]. Here, CCR5 is linked to metabolic dysfunction-associated steatohepatitis.